AbbVie Inc. $ABBV Stock: Banco Santander S.A. Raises Stake

AbbVie logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Banco Santander increased its AbbVie stake 154.3% in the third quarter, adding 287,082 shares to hold 473,135 shares worth about $123.8 million. Institutional investors and hedge funds collectively own 70.23% of the stock.
  • AbbVie’s latest quarterly results beat expectations: earnings were $3.82 per share versus $3.73 forecast, while revenue rose 10.3% year over year to $17.4 billion.
  • AbbVie raised its quarterly dividend from $1.73 to $1.82 per share, equal to a 2.5% annualized yield. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $297.85.
  • MarketBeat previews the top five stocks to own by December 1st.

Banco Santander S.A. boosted its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 154.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 473,135 shares of the company's stock after buying an additional 287,082 shares during the period. AbbVie accounts for approximately 0.6% of Banco Santander S.A.'s investment portfolio, making the stock its 27th largest holding. Banco Santander S.A.'s holdings in AbbVie were worth $123,767,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. State Street Corp increased its position in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company's stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares during the period. Fisher Asset Management LLC increased its holdings in shares of AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company's stock valued at $8,760,498,000 after purchasing an additional 23,991,451 shares during the period. Corient Private Wealth LP acquired a new position in shares of AbbVie during the second quarter valued at $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock valued at $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of AbbVie during the second quarter valued at about $2,905,952,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

NYSE ABBV opened at $294.18 on Tuesday. The stock has a market capitalization of $520.00 billion, a P/E ratio of 50.63, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $302.93. The business's fifty day moving average is $276.27 and its two-hundred day moving average is $241.28.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts' consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.86 EPS. On average, research analysts forecast that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $1.82 dividend. The ex-dividend date is Friday, January 15th. This is a positive change from AbbVie's previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie's dividend payout ratio is 125.30%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABBV. Argus upped their price objective on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Piper Sandler upped their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. HSBC upped their target price on AbbVie from $300.00 to $315.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. Canaccord Genuity Group increased their price target on AbbVie from $290.00 to $338.00 and gave the company a "buy" rating in a research note on Monday, November 2nd. Finally, Oppenheimer lifted their price target on AbbVie from $244.00 to $258.00 and gave the company a "neutral" rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $297.85.

Get Our Latest Stock Report on ABBV

Insider Activity at AbbVie

In other news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares of the company's stock, valued at $24,419,005.60. This trade represents a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by insiders.

AbbVie Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Featured Stories

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines